Showing results (351-360 of 371) with videos related to

Sort By:
Pageof 38
International Journal of Radiation Oncology, Biology, Physics|July 7, 2018
Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain MetastasesPaul W Sperduto, Brian J Deegan, Jing Li, et al.
Nature Communications|March 15, 2022
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomasPriscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, et al.
The New England Journal of Medicine|July 12, 2023
BRAF-MEK Inhibition in Newly Diagnosed Papillary CraniopharyngiomasPriscilla K Brastianos, Erin Twohy, Susan Geyer, et al.
Neuro-Oncology|December 26, 2024
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant gliomaMacarena I de la Fuente, Mehdi Touat, Martin J van den Bent, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Nature Medicine|June 2, 2023
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial resultsPriscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|March 20, 2019
Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?Paul W Sperduto, Penny Fang, Jing Li, et al.
Nature Communications|October 13, 2021
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosisPriscilla K Brastianos, Matthew R Strickland, Eudocia Quant Lee, et al.
Nature Medicine|June 3, 2020
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Pageof 38